Archives

From Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist

B HONG KONG, April 1, 2026 /PRNewswire/ — The release of Innogen’s inaugural annual report following its Hong Kong listing serves not merely as a financial… Login to continue reading Login…

Read MoreFrom Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

B – Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the… Login to continue reading Login…

Read MoreBambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting